Drugs Made In America Acquisition II LLC - Sep 26, 2025 Form 4 Insider Report for Drugs Made In America Acquisition II Corp. (DMII)

Role
10%+ Owner
Signature
/s/ / Lynn Stockwell as managing member
Stock symbol
DMII
Transactions as of
Sep 26, 2025
Transactions value $
$0
Form type
4
Date filed
10/1/2025, 10:37 AM
Previous filing
Sep 25, 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Drugs Made In America Acquisition II LLC 10%+ Owner 1 EAST BROWARD BOULEVARD, SUITE 700, FORT LAUDERDALE /s/ / Lynn Stockwell as managing member 2025-10-01 0002088432

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction DMII Ordinary shares Purchase +700K +4.87% 15.1M Sep 26, 2025 Direct F1
transaction DMII Ordinary shares Other -400K -2.65% 14.7M Sep 26, 2025 Direct F2
transaction DMII Ordinary shares Sale -7.97M -54.29% 6.71M Sep 26, 2025 Direct F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction DMII Rights to receive ordinary shares Purchase +700K 700K Sep 26, 2025 Ordinary shares 700K Direct F1, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Reflects 700,000 private units acquired by the reporting person, the Issuer's sponsor. Each private unit consists of one ordinary share and one right to receive one-tenth (1/10) of an ordinary share upon the consummation of an initial business combination. The private units were purchased at $10 per unit for an aggregate purchase price of $7,000,000.
F2 As of the Transaction Date, the reporting person transferred an aggregate of 400,000 ordinary shares to certain of the Issuer's officers and directors for no consideration.
F3 As of the Transaction Date, pursuant to share transfer agreements, the reporting person transferred an aggregate of 7,966,667 ordinary shares to a number of accredited investors for consideration ranging from no consideration to $1.50 per share.
F4 The rights convert automatically into ordinary shares at the completion of the Issuer's initial business combination.